|
CA3113743A1
|
|
Methods of producing pyrazole compounds
|
|
TW201835041A
|
|
Compounds with Beta-Adrenergic Agonist and Antimuscarinic Activity
|
|
EP3576754A1
|
|
Intranasal composition of methylcobalamin
|
|
WO2018130948A1
|
|
Tapentadol nasal composition
|
|
US2018193290A1
|
|
Tapentadol nasal composition
|
|
TW201819361A
|
|
Novel indazole compounds
|
|
EP3471698A1
|
|
Topical compositions of apremilast
|
|
TW201806953A
|
|
Substituted fused pyrimidinone compounds
|
|
WO2017029609A1
|
|
Pharmaceutical composition of alogliptin and metformin
|
|
AR104185A1
|
|
PHARMACEUTICAL FORMULATIONS
|
|
MX2017012943A
|
|
Novel pyridinium compounds.
|
|
WO2016030852A1
|
|
P38 map kinase inhibiting indanyl urea compounds
|
|
WO2015170237A1
|
|
Stable solifenacin composition
|
|
TW201613941A
|
|
New fusion imidazole benzothiazole compound
|
|
WO2015132708A1
|
|
Pharmaceutical composition of roflumilast
|
|
WO2015104666A2
|
|
Pharmaceutical composition of fingolimod
|
|
TW201513866A
|
|
Low dose pharmaceutical composition and use thereof
|
|
US2013331406A1
|
|
Fused thiazolo and oxazolo pyrimidinones
|
|
CA2890270A1
|
|
Pharmaceutical composition of tapentadol for parenteral administration
|
|
US2015126530A1
|
|
Novel Substituted Imidazopyrimidines as Gpbar1 Receptor Modulators
|
